Total votes: 3

Cash and cash equivalnets June 31st 2011:

$5.2 million.

Overview:

Phylogica is a company that is engaged in the discovery and development of therapeutics directed at proteins and their interactions. The Company is engaged in the discovery of peptide-based drugs to treat inflammatory diseases. The company also uses its technology as a platform/service play to pharma/biotech comapnies.

Phylogica’s technology is based on its collection of peptides (small parts of proteins), called phylomer peptides. These phylomer peptides are drugs, which can target and disrupt the interactions of proteins that cause a variety of diseases. Phylogica uses The Blocker Trap, its yeast-to-hybrid based tool to select the phylomer/s from its collection to block the disease causing protein and create new therapies.

The company claims advanatges including:

 - no antibody royalty stack
 - manufacturing advantage since they can be synthesized
 - compatiability with alternative delivery technologies

Relationships
 - Aegis (San diego) a comapny that provide novel delivery technologies
 - Affybodies (Swedish)
 - Roche (not terms released)

The CEO has announced they feel their platofrm contract research business will result in the company being cash positive by end of year 2011.